|
|
by Claremont Creek Alerts on January 18th, 2012 
January 18, 2012 source: MedCity News
Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.
The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes.
. . .
→ Read full post: Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test
by Claremont Creek Alerts on October 10th, 2011 
October 9, 2011 source: CBS News
As part of CBS morning news, TIBION was profiled by correspondent Barry Peterson. At approximately four minutes 21 seconds into the video, see how TIBION stands out. We are proud of our portfolio company that is getting worldwide recognition.
The next step in bionics
…
The new world of high-tech prosthetics includes the Tibion Bionic limb, that helps stroke victims re-learn how to use . . .
→ Read full post: Claremont Creek Ventures portfolio company Tibion’s VP of Engineering Matt Murphy shows off the Tibion Bionic Limb on CBS Morning News
by John Steuart on September 12th, 2011 
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.
In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)
by John Steuart on August 29th, 2011 
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment.
These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine the size of a market and how to assess a competitive landscape.
Startups that surmount these challenges then have . . .
→ Read full post: Sam Colella of Versant Ventures, Risa Stack of Kleiner Perkins and Alex de Winter of Mohr Davidow join me for the Molecular Diagnostics World Congress Event on September 29 at 5:15pm
by John Steuart on July 22nd, 2011 
I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center.
Here’s the panel topic summary, hope to see you there.
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These . . .
→ Read full post: Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation
by Brad Webb on July 6th, 2011 July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb
Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare
It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product
by Nat Goldhaber on July 6th, 2011 I was chatting recently with Venture Capital Journal’s Mark Boslet about a story concerning corporate venture capital investing and realized that Claremont Creek Ventures is among those VC firms witnessing first-hand heightened interest among corporations investing in venture-backed startups. We’re seeing activity, in particular, in healthcare and in clean technology, and it’s a good thing. It increases startup access to capital. And it may help startups leverage corporate brands and distribution networks to . . .
→ Read full post: Claremont Creek Ventures Sees An Uptick In Corporate Venture Capital: Interest Leverages Growth For Portfolio Companies
May 11, 2011 source: Wall Street Journal Health Blog
Public Education and Gene Testing to Improve Medication Adherence
There are tons of reasons why people don’t take the medications they’ve been prescribed, including side effects, cost and complicated drug regimens.
A couple of different approaches to improving adherence are in the news today. The first is Script Your Future, a multi-year public-education campaign spearheaded by the National Consumers League and supported by health-industry companies, . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx featured in WSJ article
by Claremont Creek Alerts on April 6th, 2011 April 5, 2011 source: Gene Security Network press release
Gene Security Network (GSN) welcomes the birth of the first baby to be born following the use of GSN’s novel Parental SupportTM technology for single gene preimplantation genetic diagnosis (PGD) and concurrent 24-chromosome screening. This test allows couples who are at risk to have children with genetic disease to undergo embryo testing during an in vitro fertilization (IVF) cycle in order to . . .
→ Read full post: Claremont Creek Ventures portfolio company GSN’s testing technology helps couple achieve their dream of a healthy child
by Claremont Creek Alerts on March 25th, 2011 March 25, 2011 source: VentureWire by Timothy Hay
AssureRx Health Inc. has raised an $11 million Series B round from Sequoia Capital and Claremont Creek Ventures for its testing system that helps psychiatric patients find the most compatible medications, according to an investor.
“This could be one of the biggest diagnostic companies of the decade, in my estimation,” said John Steuart, a Claremont Creek co-founder and managing director who takes . . .
→ Read full post: AssureRx Pulls Together $11M For Psych Diagnostics
|
